Immunogenicity, Safety, and Immune Persistence of One Dose of SARS-CoV-2 Recombinant Adenovirus Type-5 Vectored Vaccine in Children and Adolescents Aged 6-17 Years: An Immunobridging Trial.
Xu HanMingwei WeiXiuyu ZhengPeng WanJie TangLu ZhangShupeng ZhangHanchi ZhouJiayu LuLi ZhouYawen ZhuJingxin LiFengcai ZhuPublished in: Vaccines (2024)
virus particles/dose is safe in children and adolescents, and it elicited significant immune response, which was not only non-inferior but also superior to that in adults aged 18-59 years.